OCTREOTIDE ACETATE
| Brand name | BYNFEZIA PEN |
|---|---|
| Active ingredient | OCTREOTIDE ACETATE |
| Strength | EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML) |
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Modality | Small molecule |
| FDA approval | September 2024 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12350475 | December 2041 | use U-4009 |
| 11246991 | November 2040 | use U-4009 |
| 11534553 | November 2040 | use U-4009 |
| 11052196 | November 2040 | use U-4009 |
| 10342850 | May 2038 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.